Differing protection with aspartate and glutamate cardioplegia in the isolated rat heart.
Aspartate and glutamate each have been shown to improve cardiac recovery after hypoxia or ischemia under normothermic conditions, but whether their effects are additive and to what extent they are modified by hypothermia has not been studied systematically. We set out to compare the individual and combined protective effects of aspartate and glutamate during cardioplegic arrest under normothermic and hypothermic conditions in the rat. Using isolated working rat hearts, functional and metabolic recovery was assessed after 0.5 hours of potassium arrest at 37 degrees C or 5 hours at 2 degrees C in control hearts (C) and in hearts in which 20 mmol/L glutamate (G), 20 mmol/L aspartate (A), or both (A + G) was added to the cardioplegic solution. Under normothermic conditions, percentage recovery of prearrest work (mean +/- standard error of the mean) was as follows: C = 31.7 +/- 2.8, G = 34.8 +/- 0.2, A = 49.6 +/- 2.8*, A + G = 53.7 +/- 2.3*. Under hypothermic conditions, the values were as follows: C = 40.4 +/- 4.0, G = 45.2 +/- 2.3, A = 59.4 +/- 1.8*, A + G = 54.1 +/- 1.2* (*p < 0.01 versus C and G). Recovery of postischemic high-energy phosphate content followed the same pattern: A = A + G > G or C. Measurement of postischemic myocardial content of amino acids showed that recovery of function and energy status correlated with maintenance of myocardial levels of aspartate (r = 0.9; p < 0.01) but not glutamate.(ABSTRACT TRUNCATED AT 250 WORDS)
Pisarenko
O I
OI
Baker Medical Research Institute, Melbourne, Australia.
Rosenfeldt
F L
FL
Langley
L
L
Conyers
R A
RA
Richards
S M
SM
D000227:Adenine Nucleotides / Q000378:metabolism; D000818:Animals; D001224:Aspartic Acid / Q000378:metabolism / Q000627:therapeutic use*; D002314:Cardioplegic Solutions / Q000378:metabolism / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D018698:Glutamic Acid / Q000378:metabolism / Q000627:therapeutic use*; D006324:Heart Arrest, Induced / Q000009:adverse effects / Q000379:methods*; D066298:In Vitro Techniques; D008297:Male; D015428:Myocardial Reperfusion Injury / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009206:Myocardium / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar
D000227:Adenine Nucleotides; D002314:Cardioplegic Solutions; D001224:Aspartic Acid; D018698:Glutamic Acid